Middle East and Africa Synthetic Biology Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Products (Enzymes, Chassis Organisms, Oligonucleotides, and Xeno-Nucleic Acids), Technology (Measurement & Modeling, Cloning & Sequencing, Genome Engineering, Gene Synthesis, Nanotechnology, and Others), and Application (Medical Applications, Industrial Applications, Food and Agriculture, Environmental Applications, and Others)

The MEA synthetic biology market is expected to grow from US$ 698.02 million in 2021 to US$ 2,407.31 million by 2028; it is estimated to grow at a CAGR of 19.3% from 2021 to 2028.

Significant advancements have been seen in CRISPR-based technologies. In addition, significant funds and investments by leading synthetic biology companies continue to drive the shift in the major application of synthetic biology offerings from the textile industry to the pharmaceuticals industry. For instance, the proposal for the first clinical trials of CRISPR-based therapeutics for treating inherited diseases has been submitted to regulators, which is focused on gene editing therapy for beta-thalassemia and sickle cell disease. The most attractive targets for CRISPR-based gene therapy are genetic diseases arising from mutations. Another trend in the field of synthetic biology is set by Bolt Threads as the company has manufactured the first garment from spider silk, which is available commercially. The silk was produced by using gene-editing techniques. Further, as per the Twist Bioscience news, Spiber, a company, has collaborated with The North Face to produce a parka, which is a coat made up of ersatz spider silk. The company is yet to begin the sales of the coat, as it hasn’t worked out the cost of the coat. Such advancements in techniques and products are giving rise to new trends in the synthetic biology market, which are likely to drive the market growth in the coming years.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely

to drive the MEA synthetic biology market. The MEA synthetic biology market is expected to grow at a significant CAGR during the forecast period.

MEA Synthetic Biology Market Revenue and Forecast to 2028 (US$ Million)

MEA Synthetic Biology Market Segmentation   

The MEA synthetic biology market is analyzed based on products, technology, application, and country. Based on products, the market is segmented into enzymes, chassis organisms, oligonucleotides, and xeno-nucleic acids. The oligonucleotides segment dominated the market in 2020 and is expected to be fastest growing during the forecast period. Based on technology, the market is segmented into measurement & modeling, cloning & sequencing, genome engineering, gene synthesis, nanotechnology, and others. The gene synthesis segment dominated the market in 2020, while the genome engineering segment is expected to be fastest growing during the forecast period. Based on application, the market is segmented into medical applications, industrial applications, food and agriculture, environmental applications, and others. The medical applications segment dominated the market in 2020 and is expected to be fastest growing during forecast period. The MEA synthetic biology market is segmented into Saudi Arabia, UAE, South Africa, and Rest of MEA.

Agilent Technologies, Inc.; Amyris; Codexis; Genscript Biotech corporation; Integrated DNA Technologies; Merck KGaA; New England Biolabs; Novozymes A/S; Thermo Fisher Scientific; and Twist Bioscience are among the leading companies in the MEA synthetic biology market. 

1. Agilent Technologies, Inc.
2. Amyris
3. Codexis
4. Genscript Biotech corporation
5. Integrated DNA Technologies
6. Merck KGaA
7. New England Biolabs
8. Novozymes A/S
9. Thermo Fisher Scientific
10. Twist Bioscience

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the MEA synthetic biology market.       
• Highlights key business priorities in order to assist companies to realign their business strategies
• The key findings and recommendations highlight crucial progressive industry trends in the MEA synthetic biology market, thereby allowing players across the value chain to develop effective long-term strategies
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
• Scrutinize in-depth MEA market trends and outlook coupled with the factors driving the synthetic biology market, as well as those hindering it
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution